Fulgent Genetics, Inc.

FLGT Healthcare Diagnostics & Research

Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4.38%, EPS fell 69.4% and free cash flow grew 25.4%, each against the same quarter a year earlier.

19.81 1.53 −7.17%
Market cap
$587.2M
P/E
0.0×
Fwd P/E
−5.8×
Dividend yield
—
F-score
4/9
Altman Z
5.63
Beneish M
−2.35
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
1.77 1.53 2.51 2.20
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(24.19) 69.19 (10.35) 62.57
P/B ratio
0.58 0.47 0.73 0.62
EV/Sales
1.05 0.74 1.53 1.08
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(3.26) (2.08) (3.97) (17.14)
Current Ratio
6.34 5.31 6.48 7.01
Net Debt/EBITDA
8.82 9.36 8.20 778.06
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(13.74%) (15.03%) (7.46%) (6.15%)
Free Cash Flow Yield
(18.06%) (23.05%) (15.36%) (2.86%)
Free Cash Flow per Share
(0.99) 0.06 (2.70) 0.16
Book value per Share
35.56 33.81 35.96 36.45
Free Cash Flow
(27.62) 1.90 (83.12) 5.06
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates